Meeting
2019 ASCO Annual Meeting
Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
Authors
Ali Belkouz
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Ali Belkouz , Judith de Vos-Geelen , Ferry Eskens , Ron A.A. Mathot , Thomas van Gulik , Martijn G.H. van Oijen , Cornelis J. A. Punt , Johanna Wilmink , Heinz-Josef Kluempen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02456714
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4086)
DOI
10.1200/JCO.2019.37.15_suppl.4086
Abstract #
4086
Poster Bd #
191
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando